FLOW showed semaglutide reduces major kidney events 24% in adults with T2D and CKD. Stopped early for efficacy. Establishes semaglutide alongside SGLT2 inhibitors as a renoprotective agent in T2D + CKD.

Trial design

FLOW (Perkovic et al., NEJM 2024) enrolled 3,533 adults with T2D and stage 2–4 CKD (eGFR 25–75 mL/min/1.73m² with elevated albuminuria). Randomized to semaglutide 1.0 mg weekly or placebo, on top of standard renoprotective therapy (ACE/ARB).

Results

Trial stopped early for efficacy. Median trial duration 3.4 years.

Mechanism

Beyond glycemic and weight effects, GLP-1 receptor agonists appear to have direct renoprotective effects: reduced glomerular hyperfiltration, reduced oxidative stress, anti-inflammatory effects on renal interstitium, BP reduction. Benefit appears additive to ACE/ARB and complementary to SGLT2 inhibitor.

Practical implications

What about CKD without diabetes?

FLOW was T2D-only. The FLOW-NoDM trial program is enrolling. Mechanism would suggest benefit; trial evidence is forthcoming.

Dose consideration

FLOW used semaglutide 1.0 mg weekly — not the 2.4 mg used for weight indications. Some compounded programs default to titrations targeting weight loss endpoints; patients with CKD-directed treatment goals should discuss target dose with their prescriber.

See our detailed kidney disease page.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.